ClinicalTrials.gg
RecruitingNCT07414849AMPERUpdated Jun 17, 2026

The AMPER Study: Evaluation of the Efficacy of Human Amniotic Membrane Grafting in Preventing Mesh Exposure in Vaginal Reconstructive Surgery Using Polypropylene Mesh.

An interventional study of Sacrospinous Hysteropexy with Mesh and Retropubic Mid-urethral Sling (Bottom-Up) in Pelvic Organ Prolapse Vaginal Surgery and Stress Urinary Incontinence in Women, sponsored by Hospital General de Agudos J. M. Penna. Recruiting at 1 site in Argentina. Open to female participants. Per ClinicalTrials.gov, last updated 2026-06-17.

Primary conditionUterine ProlapseRegistry: Pelvic Organ ProlapseReclassifiedWhy we changed it
Registry
Pelvic Organ Prolapse — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Prolapse
Why
  1. The study's listed conditions name Uterine Prolapse, a narrower term within Pelvic Organ Prolapse.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospital General de Agudos J. M. Penna · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
330
Allocation
Randomized
Sex
Female
01

Study summary

This study evaluates the efficacy of adding a human amniotic membrane graft to polypropylene mesh surgery for pelvic prolapse and stress urinary incontinence. The goal is to assess improvements in tissue integration and the reduction of surgical complications

02

Conditions studied

  • Pelvic Organ Prolapse Vaginal Surgery
  • Stress Urinary Incontinence in Women

Browse trials for

Keywords

  • amniotic membrane graft
  • polypropylene mesh
03

In context

Uterine Prolapse Reclassified

111 studies on the registry are indexed under Uterine Prolapse; 18 are open to participants now.

This study's planned enrollment of 330 is above the median of 70 across 76 interventional studies indexed under Uterine Prolapse.

Browse Uterine Prolapse studies →

Lead sponsor

This is the only study on the registry with Hospital General de Agudos J. M. Penna as lead sponsor.

Compared within Uterine Prolapse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pelvic Organ Prolapse. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pelvic organ prolapse (POP) stage II C or greater, defined as C ≥ +1, in women without prior hysterectomy and/or with a diagnosis of stress urinary incontinence seeking surgical treatment.
  • Ability to understand study information and provide written .
  • Availability for follow-up for a minimum of 12 months.

Exclusion criteria

Exclusion Criteria:

  • Previous surgery with synthetic mesh (via vaginal or abdominal approach) for POP repair.
  • Known adverse reaction to synthetic meshes.
  • Unresolved or active chronic pelvic pain.
  • History of prior abdominal or pelvic radiation.
  • to the planned surgical procedure.
  • Current pregnancy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
330 participants (estimated)

Study arms

  • Experimental
    With amniotic membrane

    Patients undergoing surgery for pelvic organ prolapse or stress urinary incontinence with polypropylene mesh in whom a dehydrated human amniotic membrane patch was placed over the mesh or sling prior to vaginal closure.

    Procedure: Sacrospinous Hysteropexy with Mesh · Procedure: Retropubic Mid-urethral Sling (Bottom-Up) · Procedure: Transobturator Mid-urethral Sling (Out-In)

  • Active comparator
    without amniotic membrane, surgery alone

    Patients undergoing surgery for pelvic organ prolapse or stress urinary incontinence with polypropylene mesh without human amniotic membrane patch

    Procedure: Sacrospinous Hysteropexy with Mesh · Procedure: Retropubic Mid-urethral Sling (Bottom-Up) · Procedure: Transobturator Mid-urethral Sling (Out-In)

Interventions

  • ProcedureSacrospinous Hysteropexy with Mesh

    Sacrospinous Hysteropexy with polypropylene mesh

  • ProcedureRetropubic Mid-urethral Sling (Bottom-Up)

    Retropubic mid-urethral sling (bottom-up approach) using polypropylene mesh for the treatment of stress urinary incontinence.

  • ProcedureTransobturator Mid-urethral Sling (Out-In)

    Transobturator mid-urethral sling (out-in) using polypropylene mesh for the treatment of stress urinary incontinence.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Mesh exposure

    Comparison of mesh exposure incidence between the control group and the amniotic membrane group through scheduled postoperative follow-up and self-administered questionnaires.

    Time frame: From enrollment through the end of the 12-month follow-up

07

Study locations

1 of 1 sites recruiting
  • Hospital J M Penna
    Buenos Aires, Argentina
    Recruiting
    • Ileana Sanger, MD · ContactIlesaenger@gmail.com · 549114911-5555
    • Ileana Sanger, MD · Principal investigator
08

References and documents

Publications

  • Jacquetin B, Hinoul P, Gauld J, Fatton B, Rosenthal C, Clave H, Garbin O, Berrocal J, Villet R, Salet-Lizee D, Debodinance P, Cosson M. Total transvaginal mesh (TVM) technique for treatment of pelvic organ prolapse: a 5-year prospective follow-up study. Int Urogynecol J. 2013 Oct;24(10):1679-86. doi: 10.1007/s00192-013-2080-4. Epub 2013 Apr 6. PubMed 23563891 ↗
  • Willison N, McPhail C, Seman E, Taheri M, Aryan P, Nguyen T, Yi J, Abbott D, Dune T, Behnia-Willison F. Platelet-Rich Plasma and Fractional CO2 Laser Therapy to Reduce Surgical Intervention for Symptomatic Vaginal Mesh-Related Complications. Int Urogynecol J. 2025 Apr;36(4):903-912. doi: 10.1007/s00192-025-06123-z. Epub 2025 Apr 3. PubMed 40178545 ↗
  • Meutia AP, Budinurdjaja P, Fauzi A, Boediono A, Djusad S, Prihartono J, Wuyung PE, Hestiantoro A, Santoso BI. Enhancing Mesh-Tissue Integration in Menopausal Models Using a Platelet-Rich Plasma-Decellularized Amnion Scaffold Sandwich: A Study on Mesh Contraction, Inflammatory Infiltrate, IL-17, CD31, and Collagen Deposition. Int Urogynecol J. 2025 May;36(5):1045-1052. doi: 10.1007/s00192-025-06084-3. Epub 2025 Mar 5. PubMed 40042603 ↗
  • Lau HH, Jou QB, Huang WC, Su TH. Amniotic Membrane Graft in the Management of Complex Vaginal Mesh Erosion. J Clin Med. 2020 Jan 28;9(2):356. doi: 10.3390/jcm9020356. PubMed 32012905 ↗
  • Dibb B, Woodgate F, Taylor L. When things go wrong: experiences of vaginal mesh complications. Int Urogynecol J. 2023 Jul;34(7):1575-1581. doi: 10.1007/s00192-022-05422-z. Epub 2023 Jan 6. PubMed 36607398 ↗
  • Siblini T, Baracy M, Kulkarni S, Mabis C, Hagglund K, Aslam M. Midurethral Sling Mesh Exposure Confers a High Risk of Persistent Stress Urinary Incontinence. Int Urogynecol J. 2024 Jun;35(6):1177-1182. doi: 10.1007/s00192-024-05762-y. Epub 2024 May 4. PubMed 38703222 ↗
  • Six JC, Pinsard M, Guerin S, Gasmi A, Coiffic J, Richard C, Haudebert C, Nyangoh Timoh K, Hascoet J, Peyronnet B. Risk factors for stress urinary incontinence recurrence after midurethral sling revision. Int J Urol. 2023 Nov;30(11):1008-1013. doi: 10.1111/iju.15248. Epub 2023 Jul 13. PubMed 37439555 ↗
  • Maher CF, Yeung E, Chen Z, Masel A, Smith D, Lourie R, Devan SM, Rasch R, Uwins P, Blakey I, Boyle GM, Jones L. Pathogenesis of polypropylene mesh complications in female pelvic floor surgery. Am J Obstet Gynecol. 2025 Oct;233(4):309.e1-309.e11. doi: 10.1016/j.ajog.2025.03.009. Epub 2025 Mar 10. PubMed 40073920 ↗
  • Liang R, Knight K, Abramowitch S, Moalli PA. Exploring the basic science of prolapse meshes. Curr Opin Obstet Gynecol. 2016 Oct;28(5):413-9. doi: 10.1097/GCO.0000000000000313. PubMed 27517341 ↗
  • Page AS, Cattani L, Pacquee S, Claerhout F, Callewaert G, Housmans S, Van der Aa F, D'Hoore A, Deprest J. Long-term Data on Graft-Related Complications After Sacrocolpopexy With Lightweight Compared With Heavier-Weight Mesh. Obstet Gynecol. 2023 Jan 1;141(1):189-198. doi: 10.1097/AOG.0000000000005021. Epub 2022 Nov 30. PubMed 36701619 ↗
  • Hofmann N, Rennekampff HO, Salz AK, Borgel M. Preparation of human amniotic membrane for transplantation in different application areas. Front Transplant. 2023 May 5;2:1152068. doi: 10.3389/frtra.2023.1152068. eCollection 2023. PubMed 38993896 ↗
  • Jahanafrooz Z, Bakhshandeh B, Behnam Abdollahi S, Seyedjafari E. Human amniotic membrane as a multifunctional biomaterial: recent advances and applications. J Biomater Appl. 2023 Mar;37(8):1341-1354. doi: 10.1177/08853282221137609. Epub 2022 Nov 4. PubMed 36331116 ↗
  • Abbott S, Unger CA, Evans JM, Jallad K, Mishra K, Karram MM, Iglesia CB, Rardin CR, Barber MD. Evaluation and management of complications from synthetic mesh after pelvic reconstructive surgery: a multicenter study. Am J Obstet Gynecol. 2014 Feb;210(2):163.e1-8. doi: 10.1016/j.ajog.2013.10.012. Epub 2013 Oct 11. PubMed 24126300 ↗
  • Giusto LL, Zahner PM, Goldman HB. Management of the Exposed or Perforated Midurethral Sling. Urol Clin North Am. 2019 Feb;46(1):31-40. doi: 10.1016/j.ucl.2018.08.003. PubMed 30466700 ↗
  • Mao J, Chughtai B, Ibrahim S, Sedrakyan A. Food and Drug Administration Safety Communication on the Use of Transvaginal Mesh in Pelvic Organ Prolapse Repair Surgery: The Impact of Social Determinants of Health. Female Pelvic Med Reconstr Surg. 2021 Jan 1;27(1):e133-e138. doi: 10.1097/SPV.0000000000000863. PubMed 32453208 ↗
  • Guler Sonmez T, Ugras E, Gul Sahin E, Fidanci I, Aksoy H, Ayhan Baser D. The prevalence of incontinence and its impact on quality of life. Medicine (Baltimore). 2024 Dec 27;103(52):e41108. doi: 10.1097/MD.0000000000041108. PubMed 39969293 ↗
  • de Tayrac R, Antosh DD, Baessler K, Cheon C, Deffieux X, Gutman R, Lee J, Nager C, Schizas A, Sung V, Maher C. Summary: 2021 International Consultation on Incontinence Evidence-Based Surgical Pathway for Pelvic Organ Prolapse. J Clin Med. 2022 Oct 17;11(20):6106. doi: 10.3390/jcm11206106. PubMed 36294427 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

Of 37 interventional studies with no phase under Uterine Prolapse, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 68. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 17, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07414849
Lead sponsor
Hospital General de Agudos J. M. Penna
Responsible party
Ileana Sänger (Head of Gynecology, Department of Obstetrics and Gynecology, Hospital General de Agudos J. M. Penna) — Principal investigator
First posted
Feb 17, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jun 17, 2026

Study contacts

Ileana Sanger, MD
Contact
ilesaenger@me.com
5491149113030

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion